Doxorubicin Active Not Recruiting Phase 2 Trials for Stage I Breast Carcinoma / Breast Cancer / Stage II Breast Cancer / Stage III Breast Cancer Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02096588Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
NCT02132949A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
NCT02499367Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients
NCT02833766Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
NCT03248427Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.
NCT01210768A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients
NCT00295893Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
NCT01593020Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
NCT00003042Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
NCT03712956CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER
NCT01990352Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
NCT01670500Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
NCT00206518Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
NCT00580333Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
NCT01796197Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
NCT01147016Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
NCT00856492S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer